Psoriasis showdown: which drug clears skin faster?

NCT ID NCT06333860

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two already-approved drugs, risankizumab (injection) and deucravacitinib (pill), for adults with moderate plaque psoriasis. About 393 participants who haven't used biologics before will receive one of the treatments for up to 44 weeks. The goal is to see which drug better clears skin and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: risankizumab and deucravacitinib
What this could lead to: If this trial shows one drug works better, it could help doctors choose the most effective treatment for moderate plaque psoriasis.
What could go wrong: Both drugs are already approved, so this is a head-to-head comparison, not a breakthrough. Results may not apply to everyone with psoriasis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

393 people

The number who actually took part.

Started

May 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant with a diagnosis of chronic plaque psoriasis (PsO) with or without psoriatic arthritis, for at least 6 months prior to Baseline. * Stable moderate chronic plaque psoriasis at both Screening and Baseline as defined as: * Body Surface Area (BSA) ≥ 10% and ≤ 15%, * Psoriasis Area and Severity Index (PASI) ≥ 12, and * Static Physician Global Assessment (sPGA) = 3 (moderate) based on a 5-point scale (0 to 4). * Participant must be a candidate for systemic therapy as assessed by the investigator * Psoriasis inadequately controlled by topicals, phototherapy and/or systemic treatments (including, but not limited to, methotrexate, apremilast, cyclosporine A, corticosteroids, and/or cyclophosphamide) Exclusion Criteria: * Participants with any form of PsO other than chronic plaque PsO (e.g., pustular PsO, palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic, or guttate PsO). * Participants with a history of current drug-induced PsO or a drug-induced exacerbation of preexisting PsO. * Participants with a history of active ongoing inflammatory skin diseases other than PsO (with or without PsA) that could interfere with the assessment of PsO (e.g., hyperkeratotic eczema). * Participants with a history of severe renal insufficiency defined as creatinine clearance \< 30 mL/min and/or requiring hemodialysis or peritoneal dialysis. * Participantswith a history of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months. * Participants with a history of an allergic reaction or significant sensitivity to constituents of the study drugs (and its excipients) and/or other products in the same class. * Participants who have had major surgery performed within 12 weeks prior to randomization or planned during the conduct of the study (e.g., hip replacement, aneurysm removal, stomach ligation). * Participants with evidence of: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, defined as: * HBV: Hepatitis B surface antigen (HBs Ag) positive (+) test or detected sensitivity on the HBV DNA PCR qualitative test for subjects who are hepatitis B core antibody (HBc Ab) positive (+) (and for hepatitis B surface antibody \[HBs Ab\] positive \[+\] participants where mandated by local requirements). * HCV: HCV RNA detectable in any participant with anti-HCV antibody (HCV Ab). * Human immunodeficiency virus (HIV), defined as confirmed positive anti-HIV Ab test and considered to have unstable disease (Unless meeting criteria for stable disease) Participants with HIV with no history of AIDS-defining conditions AND stable disease for at least 6 months prior to screening can be enrolled. Criteria for stable disease is achieved if all below criteria are met. Documentation of "stable disease" can be done at the Screening visit or by documentation of labs performed within 1 month of the Randomization visit, in addition to the subject's medical history. * On stable antiretroviral therapy; * Viral load (HIV RNA) below the lower limit of quantification by a validated and approved plasma HIV-1 RNA quantitative assay; * CD4+ T cell count ≥ 500 cells/μL. \- Participants with any of the following medical diseases or disorders: * Recent (within past 6 months) cerebrovascular accident or myocardial infarction; * History of an organ transplant which requires continued immunosuppression; * Active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix. * Prior history of suicide attempt at any time in the subject's lifetime prior to signing the informed consent and randomization, or major depression or suicidal ideation or attempt requiring hospitalization within the last 3 years prior to signing the informed consent. * Hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. \- Participants who received within 30 days prior to Baseline any: * Other systemic immunomodulating treatments (including, but not limited to: e.g., methotrexate, apremilast, cyclosporine A, corticosteroids, cyclophosphamide, tofacitinib \[Xeljanz®\]); * Other systemic PsO treatments (e.g., retinoids, fumarates, any other drug known to possibly benefit PsO); * Photochemotherapy (e.g., PUVA), phototherapy (e.g., UVB) or prolonged exposure or use of tanning booths or ultraviolet light sources. * Participants who received within 14 days prior to Baseline any topical treatment for PsO or any other skin condition (including, but not limited to: e.g., corticosteroids, vitamin D analogues, vitamin A analogues, pimecrolimus, retinoids, salicyl vaseline, salicylic acid, lactic acid, tacrolimus, tar, urea, or anthralin). * Participants who have been treated with any strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin, St. John's Wort) within 30 days or 5 half-lives of start of treatment with deucravacitinib. * Participants who received any live viral or bacterial vaccine within 4 weeks prior to the first dose of study drug, or expect the need for live vaccination during study participation including at least 147 days (21 weeks or as guided by the local risankizumab label \[if approved\], whichever is longer) after the last dose of risankizumab or at least 30 days after the last dose of deucravacitinib. * Participants who have been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or be currently enrolled in another interventional clinical study.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate plaque psoriasis

Contacts and locations

Locations

Advanced Clinical Research Institute /ID# 263878

Tampa, Florida, 33607, United States
Advanced Research Associates - Glendale /ID# 263621

Glendale, Arizona, 85308, United States
Amsterdam UMC, locatie AMC /ID# 263550

Amsterdam, North Holland, 1105 AZ, Netherlands
Arlington Dermatology /ID# 263001

Rolling Meadows, Illinois, 60008, United States
Arlington Research Center, Inc /ID# 263908

Arlington, Texas, 76011, United States
Azienda Ospedaliero Universitaria Pisana /ID# 263468

Pisa, 56126, Italy
Beacon Dermatology Inc /ID# 264266

Calgary, Alberta, T3A 2N1, Canada
Beldio Research GmbH /ID# 263073

Memmingen, Bavaria, 87700, Germany
Bellaire Dermatology Associates /ID# 263897

Bellaire, Texas, 77401, United States
CHU de Liege /ID# 263108

Liège, 4000, Belgium
Center for Clinical Studies - Clear Lake /ID# 263009

Webster, Texas, 77598, United States
Center for Clinical Studies - Clear Lake /ID# 263917

Webster, Texas, 77598, United States
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 263955

Berlin, 10117, Germany
Clear Dermatology & Aesthetics Center /ID# 263626

Scottsdale, Arizona, 85260, United States
Clearlyderm Dermatology - West Boca /ID# 264963

Boca Raton, Florida, 33428, United States
Clinical Partners /ID# 263862

Johnston, Rhode Island, 02919, United States
Clinical Research Institute of Michigan - Clinton Township Office /ID# 264968

Clinton Township, Michigan, 48038, United States
Clinical Research Puerto Rico /ID# 263213

San Juan, 00909-1711, Puerto Rico
Cliniques Universitaires UCL Saint-Luc /ID# 263106

Brussels, Brussels Capital, 1200, Belgium
Dawes Fretzin, LLC /ID# 264578

Indianapolis, Indiana, 46256, United States
Debreceni Egyetem-Klinikai Kozpont /ID# 263484

Debrecen, Hajdú-Bihar, 4032, Hungary
Derm-surg /ID# 263799

Kaposvár, Somogy County, 7400, Hungary
Dermatologie Mahlow /ID# 263072

Blankenfelde-Mahlow, Brandenburg, 15831, Germany
Dermatology Clinical Research Center of San Antonio /ID# 263869

San Antonio, Texas, 78229, United States
Dermatology Research Institute - Blackfoot Trail /ID# 264476

Calgary, Alberta, T2J 7E1, Canada
Dermatology Treatment and Research Center /ID# 267071

Dallas, Texas, 75230, United States
Dermatology Trial Associates /ID# 264480

Bryant, Arkansas, 72022, United States
Dermatology and Skin Center of Lees Summit /ID# 263560

Lee's Summit, Missouri, 64064-2301, United States
Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 262981

London, Greater London, E1 2ES, United Kingdom
Driven Research /ID# 263002

Coral Gables, Florida, 33134, United States
Duplicate_Azienda Ospedaliera Universitaria Federico II /ID# 264034

Naples, Napoli, 80131, Italy
Fachklinik - Bad Bentheim /ID# 263066

Bad Bentheim, Lower Saxony, 48455, Germany
First OC Dermatology /ID# 263003

Fountain Valley, California, 92708, United States
GCM Medical Group, PSC /ID# 263198

San Juan, 00917, Puerto Rico
General Hospital Andreas Syggros /ID# 263418

Athens, Attica, 16121, Greece
General Hospital Andreas Syggros /ID# 263708

Athens, Attica, 16121, Greece
Hautarztpraxis Langenau /ID# 263070

Langenau, Baden-Wurttemberg, 89129, Germany
Health Concepts /ID# 263016

Rapid City, South Dakota, 57702, United States
Hospital Clinic de Barcelona /ID# 263040

Barcelona, 08036, Spain
Hospital General Universitario de Alicante Doctor Balmis /ID# 262977

Alicante, 03010, Spain
Hospital Universitario de La Princesa /ID# 262980

Madrid, 28006, Spain
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 263419

Thessaloniki, 54643, Greece
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 263986

Bologna, 40138, Italy
IRCCS Istituto Clinico Humanitas /ID# 263466

Rozzano, Lombardy, 20089, Italy
Integrative Skin Science and Research /ID# 264504

Sacramento, California, 95815, United States
International Dermatology Research /ID# 264911

Miami, Florida, 33144, United States
Lenus Research and Medical Group /ID# 263886

Miami, Florida, 33172, United States
Medderm Associates Dermatology /ID# 263858

San Diego, California, 92103, United States
MetroBoston Clinical Partners /ID# 263860

Boston, Massachusetts, 02135-3511, United States
Mindful Medical Research /ID# 263201

San Juan, 00918-3756, Puerto Rico
Northern Care Alliance NHS Group /ID# 262983

Salford, M6 8HD, United Kingdom
Oregon Dermatology & Research Center /ID# 263674

Portland, Oregon, 97210, United States
Pan American Center for Oncology Trials /ID# 263206

Rio Piedras, 00935, Puerto Rico
Papageorgiou General Hospital /ID# 263414

Thessaloniki, 56429, Greece
Paratus Clinical Research Woden /ID# 263120

Phillip, Australian Capital Territory, 2606, Australia
Physician Research Collaboration, LLC /ID# 263568

Lincoln, Nebraska, 68516, United States
Physioseq, LLC /ID# 265035

Sacramento, California, 95825, United States
Premier Clinical Research /ID# 263679

Spokane, Washington, 99202, United States
Premier Dermatology /ID# 263119

Kogarah, New South Wales, 2217, Australia
Private Practice - Dr. Alma Cruz /ID# 263212

Carolina, 00985, Puerto Rico
Private Practice - Dr. Angelique Gagne-Henley /ID# 264267

Saint-Jérôme, Quebec, J7Z 7E2, Canada
Private Practice - Dr. Kim Papp Clinical Research /ID# 264269

Waterloo, Ontario, N2J 1C4, Canada
Semmelweis Egyetem /ID# 263483

Budapest, 1085, Hungary
Sinclair Dermatology - Melbourne /ID# 262997

East Melbourne, Victoria, 3002, Australia
Skin Cancer and Dermatology Institute - Reno /ID# 263697

Reno, Nevada, 89509, United States
Skin Care Research - Hollywood /ID# 263877

Hollywood, Florida, 33021-6748, United States
Skin Care Research - Tampa /ID# 263880

Tampa, Florida, 33607-6438, United States
Skin Health Institute /ID# 263116

Carlton, Victoria, 3053, Australia
Southern California Dermatology /ID# 263021

Santa Ana, California, 92701, United States
Spaarne Gasthuis - Hoofddorp /ID# 263165

Hoofddorp, North Holland, 2134 TM, Netherlands
StracSkin, PLLC /ID# 263024

Portsmouth, New Hampshire, 03801, United States
Szegedi Tudomanyegyetem /ID# 263800

Szeged, 6720, Hungary
Texas Dermatology Research Center /ID# 264487

Plano, Texas, 75025, United States
The Skin Hospital - Sydney /ID# 263634

Sydney, New South Wales, 2010, Australia
Toronto Dermatology Centre /ID# 264273

Toronto, Ontario, M3H 5Y8, Canada
Total Skin and Beauty Dermatology Center /ID# 263011

Birmingham, Alabama, 35205, United States
U.S. Dermatology Partners - Cedar Park /ID# 263906

Cedar Park, Texas, 78613, United States
UNO Medical Trials /ID# 263478

Budapest, 1135, Hungary
UZ Gent /ID# 263107

Ghent, Oost-Vlaanderen, 9000, Belgium
Universitaetsklinikum Freiburg /ID# 263069

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Universitaetsklinikum Muenster /ID# 263061

Münster, North Rhine-Westphalia, 48149, Germany
University Dermatology and Vein Clinic, LLC /ID# 263028

Chicago, Illinois, 60640-7972, United States
University General Hospital Attikon /ID# 263421

Athens, Attica, 12462, Greece
University of Michigan Health System - Ann Arbor /ID# 265233

Ann Arbor, Michigan, 48109, United States
Veracity Clinical Research /ID# 263091

Woolloongabba, Queensland, 4102, Australia
Victoria Hospital /ID# 262984

Kirkcaldy, Fife, KY2 5AH, United Kingdom
Wellness Clinical Research - Miami Lakes /ID# 263887

Miami Lakes, Florida, 33016, United States
Wiseman Dermatology Research /ID# 265317

Winnipeg, Manitoba, R3M 3Z4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.